Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS

Heinz Wiendl; Bernd Kieseier

doi:10.1038/nrneurol.2013.2

Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS

Nat Rev Neurol. 2013 Mar;9(3):125-6. doi: 10.1038/nrneurol.2013.2. Epub 2013 Jan 29.

Authors

Heinz Wiendl¹, Bernd Kieseier

Affiliation

¹ Department of Neurology, University of Münster, Albert-Schweitzer-Campus 1, 48129 Münster, Germany. heinz.wiendl@ukmuenster.de

PMID: 23358486
DOI: 10.1038/nrneurol.2013.2

Abstract

Results from two phase III trials show the potency of alemtuzumab—a T-cell and B-cell depleting antibody—in reducing clinical and paraclinical measures of disease activity in relapsing–remitting multiple sclerosis. The effects of this immunotherapeutic agent highlight the relevance of T lymphocytes in the early pathogenesis of disease.

MeSH terms

Alemtuzumab
Antibodies, Monoclonal, Humanized / therapeutic use*
Antigens, CD / immunology
Antigens, Neoplasm / immunology
CD52 Antigen
Clinical Trials, Phase III as Topic
Glycoproteins / immunology
Humans
Multiple Sclerosis / immunology*
Multiple Sclerosis / therapy*

Substances

Antibodies, Monoclonal, Humanized
Antigens, CD
Antigens, Neoplasm
CD52 Antigen
CD52 protein, human
Glycoproteins
Alemtuzumab